SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned programs expected to enter clinical trials in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million

Expansion of agreement results in an additional payment of $22 million to Nurix SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic

SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will present a corporate overview at the 39th Annual